COMMUNIQUÉS West-GlobeNewswire

Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase
01/10/2025
PALO ALTO, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non- [...]
Omada Health Launches “Meal Map,” an AI-Powered Nutrition Experience Focused on Nutrient Quality, Not Calorie Counting
01/10/2025
The approach defies the restrictive weight loss paradigm, with early results indicating increased meal tracking and member engagement 1 with new real-time, personalized nutrition guidance SAN FRANCISCO, Oct. 01, 2025 ( [...]
Tessellate Bio Appoints Katie Chapman as Chief Scientific Officer
01/10/2025
NAARDEN, the Netherlands and STEVENAGE, United Kingdom, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, today announces the [...]
Athernal Bio Launches with £3.5 Million Funding from Delin Ventures
01/10/2025
Cambridge, UK, October 1, 2025 – Athernal Bio today announced its official launch alongside £3.5 million funding from founding investor Delin Ventures. The company is focused on the development of targeted [...]
Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years
01/10/2025
If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency Decision based on positive data [...]
Inventiva annonce la nomination d’Andrew Obenshain au poste de Directeur Général
01/10/2025
Daix (France), New York City (New York, Etats-Unis), le 1 er octobre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de [...]
Inventiva Appoints Andrew Obenshain as Chief Executive Officer
01/10/2025
Daix (France), New York City (New York, United States), October 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development [...]
NMDP Surpasses $100 Million Comprehensive Campaign Goal to Expand Patient Access, Remove Financial Barriers to Life-saving Transplants
01/10/2025
The announcement, made at the 18th annual NMDP Gala in Minneapolis, represents significant philanthropic support of the organization’s mission to save lives through cell therapy MINNEAPOLIS, Sept. 30, 2025 (GLOBE [...]
Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases
01/10/2025
Hinge Bio to receive $10 million upfront and is eligible to receive $95 million for the SLE indication and additional payments for other indications; includes contingent R&D investment, tiered sales royalties, and a [...]
Patient-Led NM Launches Statewide Summits and Video Campaign to Spotlight New Mexico’s Healthcare Crisis
01/10/2025
A Call for New Mexicans to Demand Policy Reform That Secures Timely Access to High-Quality Care Santa Fe, NM, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Patient-Led NM today announced the launch of a series of Healthcare [...]
SilverSneakers® Celebrates Members Anne H. Thibodeaux and Cecilia Gomez as 2025 Members of the Year
30/09/2025
National awards recognize SilverSneakers members who motivate others by demonstrating a commitment to live active, healthy lifestyles. NASHVILLE, Tenn., Sept. 30, 2025 (GLOBE NEWSWIRE) -- SilverSneakers, one of the [...]
The Joint Corp. Names Debbie L. Gonzalez Chief Marketing Officer
30/09/2025
- CMO with extensive experience in brand building, franchising and strategic growth – SCOTTSDALE, Ariz., Sept. 30, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic [...]
Amneal to Report Third Quarter 2025 Results on October 30, 2025
30/09/2025
BRIDGEWATER, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its third [...]
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
30/09/2025
NOVATO, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the appointment of Eric Olson as chief business officer (CBO) and executive vice president effective [...]
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025
30/09/2025
TARRYTOWN, N.Y., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its third quarter 2025 financial and operating results on Tuesday, October 28, 2025 [...]
NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers pour le premier semestre 2025
30/09/2025
PARIS et CAMBRIDGE, Mass., 30 sept. 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
30/09/2025
PARIS and CAMBRIDGE, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand [...]
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
30/09/2025
Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment 1 Well-controlled disease observed as [...]
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/09/2025
BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC’) therapeutics for difficult-to-treat cancers, reported [...]

Pages